## 3 Results
\begin{table}
\begin{tabular}{c c c c c c c} \hline \multicolumn{2}{c}{**Complete Repetition**} & \multicolumn{1}{c}{**SLP 60\%**} & \multicolumn{1}{c}{**SLP 75\%**} & \multicolumn{1}{c}{**BIOFIT-LP 60\%**} & \multicolumn{1}{c}{**BIOFIT-LP 75\%**} & \multicolumn{1}{c}{**OFF-SLP**} \\ \hline \multirow{4}{*}{\(\mu\)V} & SLP 60\% & - & \(-41.84\pm 4.48\) \({}^{\dagger}\) & \(-19.92\pm 8.38\) & \(-36.82\pm 9.80\) ** & 132.285 \(\pm\) 8.82 \({}^{\dagger}\) \\  & SLP 75\% & 41.84 \(\pm\) 4.48 \({}^{\dagger}\) & - & \(21.91\pm 8.16\) & 5.01 \(\pm\) 9.93 & 174.12 \(\pm\) 10.91 \({}^{\dagger}\) \\  & BIOFIT-LP 60\% & \(19.92\pm 8.38\) & \(-21.91\pm 8.16\) & - & \(-16.90\pm 5.03\) \({}^{\ast}\) & 152.21 \(\pm\) 9.76 \({}^{\dagger}\) \\  & BIOFIT-LP 75\% & 36.82 \(\pm\) 9.80 ** & \(-5.01\pm 9.93\) & \(16.90\pm 5.03\) \({}^{\ast}\) & - & 169.11 \(\pm\) 10.82 \({}^{\dagger}\) \\  & OFE-SLP & \(-132.29\pm 8.82\) \({}^{\dagger}\) & \(-174.12\pm 10.91\) \({}^{\dagger}\) & \(-152.21\pm 9.76\) \({}^{\dagger}\) & \(-169.11\pm 10.82\) \({}^{\dagger}\) & - \\ \hline \multirow{4}{*}{\(\mu\)V} & SLP 60\% & - & \(-42.02\pm 5.84\) \({}^{\dagger}\) & \(-14.30\pm 8.89\) & \(-27.64\pm 10.59\) & 104.96 \(\pm\) 8.03 \({}^{\dagger}\) \\  & SLP 75\% & 42.02 \(\pm\) 5.84 \({}^{\dagger}\) & - & \(27.73\pm 10.74\) & 14.38 \(\pm\) 13.28 & 146.98 \(\pm\) 11.84 \({}^{\dagger}\) \\  & BIOFIT-LP 60\% & 14.30 \(\pm\) 8.89 & \(-27.73\pm 10.74\) & - & \(-13.34\pm 6.40\) & 119.26 \(\pm\) 10.04 \({}^{\dagger}\) \\  & BIOFIT-LP 75\% & 27.64 \(\pm\) 10.59 & \(-14.38\pm 13.28\) & 13.34 \(\pm\) 6.40 & - & 132.60 \(\pm\) 10.86 \({}^{\dagger}\) \\  & OFE-SLP & \(-104.96\pm 8.03\) \({}^{\dagger}\) & \(-146.98\pm 11.84\) \({}^{\dagger}\) & \(-119.26\pm 10.04\) \({}^{\dagger}\) & \(-132.60\pm 10.86\) \({}^{\dagger}\) & - \\ \hline \multirow{4}{*}{\(\mu\)V} & SLP 60\% & - & \(-17.40\pm 3.41\)\({}^{\dagger}\) & \(7.25\pm 5.70\) & \(-3.14\pm 6.75\) & \(43.55\pm 6.82\) \({}^{\dagger}\) \\  & SLP 75\% & 17.40 \(\pm\) 3.41 \({}^{\dagger}\) & - & \(24.65\pm 5.99\) ** & 14.26 \(\pm\) 6.80 & 60.94 \(\pm\) 6.75 \({}^{\dagger}\) \\  & BIOFIT-LP 60\% & \(-7.25\pm 5.70\) & \(-24.65\pm 5.99\) ** & - & \(-10.39\pm 2.83\) \({}^{\ast}\) & 36.29 \(\pm\) 6.11 \({}^{\dagger}\) \\  & BIOFIT-LP 75\% & \(3.14\pm 6.75\) & \(-14.26\pm 6.80\) & \(10.39\pm 2.83\) \({}^{\ast}\) & - & 46.68 \(\pm\) 6.44 \({}^{\dagger}\) \\  & OFE-SLP & \(-43.55\pm 6.82\)\({}^{\dagger}\) & \(-60.94\pm 6.75\) \({}^{\dagger}\) & \(-36.29\pm 6.11\) \({}^{\dagger}\) & \(-46.68\pm 6.44\) \({}^{\dagger}\) & - \\ \hline \multirow{4}{*}{\(\mu\)V} & SLP 60\% & - & \(-19.78\pm 3.35\)\({}^{\dagger}\) & \(-65.39\pm 10.69\) \({}^{\dagger}\) & \(-72.54\pm 13.67\) \({}^{\dagger}\) & 10.12 \(\pm\) 9.63 \\  & SLP 75\% & 19.78 \(\pm\) 3.35 \({}^{\dagger}\) & - & \(-45.61\pm 10.58\) ** & \(-52.75\pm 12.87\) ** & 29.90 \(\pm\) 10.28 \\  & BIOFIT-LP 60\% & 65.39 \(\pm\) 10.69 \({}^{\dagger}\) & 45.61 \(\pm\) 10.58 ** & - & \(-7.14\pm 8.37\) & 75.51 \(\pm\) 10.48 \({}^{\dagger}\) \\  & BIOFIT-LP 75\% & 72.54 \(\pm\) 13.67 \({}^{\dagger}\) & 52.75 \(\pm\) 12.87 ** & 7.14 \(\pm\) 8.37 & - & 82.65 \(\pm\) 14.59 \({}^{\dagger}\) \\  & OFE-SLP & \(-10.12\pm 9.63\) & \(-29.90\pm 10.28\) & \(-75.51\pm 10.48\) \({}^{\dagger}\) & \(-82.65\pm 14.59\) \({}^{\dagger}\) & - \\ \hline \multirow{4}{*}{\(\mu\)V} & SLP 60\% & - & \(-16.22\pm 3.80\) ** & 21.96 \(\pm\) 5.64 ** & 18.32 \(\pm\) 5.72 \({}^{\ast}\) & 21.25 \(\pm\) 5.78 \({}^{\ast}\) \\  & SLP 75\% & 16.22 \(\pm\) 3.80 ** & - & \(38.17\pm 5.93\) \({}^{\dagger}\) & 34.54 \(\pm\) 6.42 \({}^{\dagger}\) & 37.46 \(\pm\) 6.87 \({}^{\dagger}\) \\ \cline{1-1}  & BIOFIT-LP 60\% & \(-21.96\pm 5.64\) ** & \(-38.17\pm 5.93\) \({}^{\dagger}\) & - & \(-6.63\pm 2.40\) & \(-0.71\pm 5.56\) \\ \cline{1-1}  & BIOFIT-LP 75\% & \(-18.32\pm 5.72\When comparing the OFE-SLP with SLP and the OFE-SLP with BIOFIT-LP, a significantly lower activation was found in the OFE-SLP for all muscle groups, in the full stroke, concentric, and eccentric phases (ES = 0.69-1.08; moderate effect size; \(p\) < 0.01-0.001), except for the tibialis anterior as compared to SLP for the full stroke and eccentric phase (ES = 0.09-0.42; effect size between small and moderate; \(p\) > 0.05); for the gastrocnemius as compared to BIOFIT-LP for the full stroke, concentric phase, and eccentric phase (ES = 0.09-0.2; small effect size; \(p\) > 0.05); and for the gastrocnemius as compared to SLP at 60% 1 RM in the eccentric phase (ES = 0.25; small effect size; \(p\) > 0.05).